JP2023530316A5 - - Google Patents
Info
- Publication number
- JP2023530316A5 JP2023530316A5 JP2022577319A JP2022577319A JP2023530316A5 JP 2023530316 A5 JP2023530316 A5 JP 2023530316A5 JP 2022577319 A JP2022577319 A JP 2022577319A JP 2022577319 A JP2022577319 A JP 2022577319A JP 2023530316 A5 JP2023530316 A5 JP 2023530316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- compound
- mds
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039742P | 2020-06-16 | 2020-06-16 | |
| US63/039,742 | 2020-06-16 | ||
| US202063056761P | 2020-07-27 | 2020-07-27 | |
| US63/056,761 | 2020-07-27 | ||
| US202163152516P | 2021-02-23 | 2021-02-23 | |
| US63/152,516 | 2021-02-23 | ||
| PCT/US2021/037377 WO2021257532A1 (en) | 2020-06-16 | 2021-06-15 | Alk2 inhibitors for the treatment of anemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530316A JP2023530316A (ja) | 2023-07-14 |
| JP2023530316A5 true JP2023530316A5 (https=) | 2024-06-28 |
Family
ID=76845323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577319A Pending JP2023530316A (ja) | 2020-06-16 | 2021-06-15 | 貧血の治療のためのａｌｋ２阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11723899B2 (https=) |
| EP (1) | EP4164641A1 (https=) |
| JP (1) | JP2023530316A (https=) |
| KR (1) | KR20230025444A (https=) |
| CN (1) | CN115968289B (https=) |
| AU (1) | AU2021292484A1 (https=) |
| CA (1) | CA3187767A1 (https=) |
| CL (2) | CL2022003511A1 (https=) |
| IL (1) | IL298767A (https=) |
| MX (1) | MX2022015900A (https=) |
| PH (1) | PH12022553501A1 (https=) |
| TW (1) | TW202214239A (https=) |
| WO (1) | WO2021257532A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113366019B (zh) | 2018-10-23 | 2024-08-27 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| JP7717065B2 (ja) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| US20250282877A1 (en) * | 2021-05-11 | 2025-09-11 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
| WO2023198114A1 (zh) * | 2022-04-13 | 2023-10-19 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004092727A2 (en) | 2003-04-11 | 2004-10-28 | Structural Genomix, Inc. | Compound libraries and methods for drug discovery |
| AU2005247699A1 (en) | 2004-05-27 | 2005-12-08 | Pfizer Inc. | Aminopyridine derivatives as selective dopamine D3 agonists |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| BRPI0607913A2 (pt) | 2005-04-08 | 2010-03-23 | Eisai R&D Man Co Ltd | agente terapÊutico para discinesia |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| PE20071241A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| CA2658362A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
| US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
| LT2714677T (lt) | 2011-05-23 | 2018-12-10 | Merck Patent Gmbh | Piridino ir pirazino dariniai |
| CN108484449A (zh) | 2011-09-09 | 2018-09-04 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| EP2964651A4 (en) | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| NZ734082A (en) | 2015-01-20 | 2019-01-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and method of using thereof |
| PE20181017A1 (es) | 2015-08-31 | 2018-06-26 | Dong A Socio Holdings Co Ltd | Compuestos heteroarilo y su uso como farmacos terapeuticos |
| MX388518B (es) * | 2016-07-20 | 2025-03-19 | Novartis Ag | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2. |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| EP4041243A4 (en) | 2019-09-27 | 2023-10-18 | Disc Medicine, Inc. | METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE |
| JP7717065B2 (ja) * | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
-
2021
- 2021-06-15 WO PCT/US2021/037377 patent/WO2021257532A1/en not_active Ceased
- 2021-06-15 EP EP21739843.7A patent/EP4164641A1/en active Pending
- 2021-06-15 KR KR1020237001508A patent/KR20230025444A/ko active Pending
- 2021-06-15 JP JP2022577319A patent/JP2023530316A/ja active Pending
- 2021-06-15 TW TW110121744A patent/TW202214239A/zh unknown
- 2021-06-15 CA CA3187767A patent/CA3187767A1/en active Pending
- 2021-06-15 AU AU2021292484A patent/AU2021292484A1/en not_active Withdrawn
- 2021-06-15 PH PH1/2022/553501A patent/PH12022553501A1/en unknown
- 2021-06-15 MX MX2022015900A patent/MX2022015900A/es unknown
- 2021-06-15 IL IL298767A patent/IL298767A/en unknown
- 2021-06-15 US US17/348,102 patent/US11723899B2/en active Active
- 2021-06-15 CN CN202180042461.3A patent/CN115968289B/zh active Active
-
2022
- 2022-12-09 CL CL2022003511A patent/CL2022003511A1/es unknown
-
2023
- 2023-06-28 US US18/343,267 patent/US12383541B2/en active Active
- 2023-06-30 CL CL2023001952A patent/CL2023001952A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023530316A5 (https=) | ||
| JP2022545835A5 (https=) | ||
| JP6532878B2 (ja) | 組合せ医薬 | |
| JP2022141916A (ja) | 癌の治療のための配合剤 | |
| JP2022501429A5 (https=) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| US20170020872A1 (en) | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors | |
| EP3703755B1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer | |
| RU2016122609A (ru) | Составы соединений азаиндола | |
| US20200230108A1 (en) | Pharmaceutical combinations | |
| WO2020034916A1 (zh) | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 | |
| JP6795518B2 (ja) | キナーゼを阻害する組成物及び方法 | |
| JP2022538817A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2019048822A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| AU2019201169A1 (en) | Pim kinase inhibitor combinations | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists | |
| JP7591283B2 (ja) | ブドウ膜黒色腫の治療のための併用療法 | |
| JP2022177119A5 (https=) | ||
| JP2021531308A5 (https=) | ||
| JP2022550040A5 (https=) | ||
| JP2019516728A (ja) | 抗がん組合せ治療 | |
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia |